BNBX

BNB Plus Corp. (NASDAQ:BNBX) ("BNB Plus" or the "Company"), today announced that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has successfully completed production of its largest order in LineaRx history. The $1.2 million order, originally announced in January 2026 with shipments completing in early May 2026, was produced at historically higher margins with zero batch failures, demonstrating the technical excellence and manufacturing reliability of the LineaDNA platform for large-scale cell-free DNA production. Notably, the Company achieved a production cadence of more than 1.5 grams per week during fulfillment of this order, a new record for LineaRx and a further demonstr

Company Treasury Exceeds $12 Million with Recently Implemented Active Yield Generation Strategy Provides Nasdaq Listing Status Update BNB Plus Corp. (NASDAQ:BNBX) ("BNB Plus" or the "Company"), a Nasdaq-listed digital asset treasury company focused on Binance's BNB token, today announced that its Board of Directors has authorized a formal review of strategic alternatives to maximize shareholder value and also provided an update on its Nasdaq listing status. Strategic Review and Treasury Value The strategic alternatives under consideration include, but are not limited to, a merger, reverse merger, business combination, acquisition, asset sale, joint venture, additional capital raisin

4 - BNB PLUS CORP. (0000744452) (Issuer)

4 - BNB PLUS CORP. (0000744452) (Issuer)

4 - BNB PLUS CORP. (0000744452) (Issuer)

4 - BNB PLUS CORP. (0000744452) (Issuer)

4 - BNB PLUS CORP. (0000744452) (Issuer)

4 - BNB PLUS CORP. (0000744452) (Issuer)

DEF 14A - BNB PLUS CORP. (0000744452) (Filer)

8-K - BNB PLUS CORP. (0000744452) (Filer)

Patent Covers the Composition of LineaRx's Proprietary Linea™ RNA Polymerase (RNAP), a Core Technology Empowering the Linea™ IVT Platform BNB Plus Corp. (NASDAQ:BNBX) ("BNBX" or the "Company"), announced today that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has been granted a European patent by the European Patent Office (EPO) related to European Patent Application No.: 21882234.4 (EP4232569A1) entitled "Compositions and Methods for RNA Synthesis." The European patent grant follows a U.S. patent grant in 2024 and covers the composition of LineaRx's chemically modified RNA polymerase (RNAP) enzyme branded Linea RNAP. The Company plans to validate the patent in key Europ

PRE 14A - BNB PLUS CORP. (0000744452) (Filer)

Provides Updated on BNB Token Holdings and Operating Company Performance BNB Plus Corp. (NASDAQ:BNBX) ("BNBX" or the "Company") today announced that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has received two new orders for LineaDNA from well-established developers of genetic medicines. Production and shipment of both orders is expected to be completed prior to June 2026. "We're pleased to receive these new orders from leading genetic medicine companies," said Clay Shorrock, President and CEO of BNBX. "We believe our continued engagements with top-tier customers demonstrates both the technical excellence of our LineaDNA platform and our continued operational execution.

4 - BNB PLUS CORP. (0000744452) (Issuer)

3 - BNB PLUS CORP. (0000744452) (Issuer)

SCHEDULE 13G - BNB PLUS CORP. (0000744452) (Subject)

10-Q - BNB PLUS CORP. (0000744452) (Filer)

8-K - BNB PLUS CORP. (0000744452) (Filer)

Digital Asset and Infrastructure Expert Joins Board to Support Strategic Growth and BNB Treasury Operations BNB Plus Corp. (NASDAQ:BNBX) ("BNBX" or the "Company"), today announced the appointment of James Haft as an Independent Director and member of the Board's Nominating Committee, effective as of February 2, 2026. Mr. Haft is a recognized pioneer in digital asset investments and decentralized finance, bringing more than 35 years of experience spanning blockchain infrastructure, emerging markets, and traditional finance. Mr. Haft has served as a managing director at Bear Stearns Inc, Furman Selz and ING Barings, where he focused on emerging markets, and founded and served as chairman

S-8 - BNB PLUS CORP. (0000744452) (Filer)

NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Digital Asset Virtual Conference, held January 27th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS HERE The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through January 30th. Please schedule 1x1 meetings here January 27th PresentationTicker(s)Africa Bitcoin Corporation Limited(OTCQB:AFBCF, JSE: BAC))VersaBank(NASDAQ:VBNK

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com BNB Plus Corp. (NASDAQ:BNBX) ("BNBX" or the "Company"), today announced that Chief Investment Officer Patrick Horsman, CFA and Chairman of the Board Joshua Kruger will present live at the Digital Asset Virtual Investor Conference hosted by Virtual InvestorConferences.com, on January 27th, 2026 at 1:00PM EST. DATE: January 27th, 2026 TIME: 1:00PM EST Register here Mr. Horsman and Mr. Kruger will be available for 1x1 meetings on January 27-29. Participants may schedule 1x1 Meetings here. The Digital Asset Virtual Investor Conference is a live,

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BNB Plus Corp. (NASDAQ:BNBX) ("BNBX" or the "Company"), today announced that Chief Investment Officer Patrick Horsman, CFA and Chairman of the Board Joshua Kruger will present live at the Digital Asset Virtual Investor Conference hosted by Virtual InvestorConferences.com, on January 27th, 2026 at 1:00PM EST. DATE: January 27th, 2026 TIME: 1:00PM EST Register here Mr. Horsman and Mr. Kruger will be available for 1x1 meetings on January 27-29. Participants may schedule 1x1 Meetings Here The Digital Asset Virtual Investor Conference is a live, interactive online event where investors are invited to ask the company questions in real-time. If att

8-K - BNB PLUS CORP. (0000744452) (Filer)

Acceleration of Multi-Year Customer Agreement Represents Largest LineaDNA Order in Company History Company Expects to Ship over $1.5M of LineaDNA in 1HCY2026 BNB Plus Corp. (NASDAQ:BNBX) ("BNBX" or the "Company"), today announced that it has received a $1.2M USD order for LineaDNA, representing the largest LineaDNA order in Company history. The order is an acceleration of an existing customer's annual purchasing cadence, consolidating what was originally planned as a two-year order cycle into an accelerated delivery schedule expected to be completed by May 2026. The order was placed by a global manufacturer of in vitro diagnostics (IVDs) under an existing supply agreement. The Company